Abstract
BackgroundThe high price of biological drugs has become progressively unsustainable to the national health system. The development of biosimilar drugs might represent an option in reducing healthcare costs.PurposeTo analyse the...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
